Stock MYMD MYMD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Delayed Nasdaq
Other stock markets
 02:51:51 2024-05-13 pm EDT 		5-day change 1st Jan Change
2.511 USD +0.45% Intraday chart for MyMD Pharmaceuticals, Inc. -17.93% -67.64%
Apr. 18 MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer CI
Apr. 09 Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer
CI
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
AQ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell
MT
Top Premarket Gainers
MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement
MT
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
BU
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split
MT
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
BU
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
BU
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Developing a first-in-class small molecule drug for inflammatory disease
AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
BU
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
CI
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023
AQ
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
BU
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYMD Stock
  4. News MyMD Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW